Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study
- 9 January 2012
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 64 (4), 1215-1226
- https://doi.org/10.1002/art.34359
Abstract
Objective To evaluate the efficacy and safety of rituximab in a randomized, double‐blind, placebo‐controlled phase III trial in patients with lupus nephritis treated concomitantly with mycophenolate mofetil (MMF) and corticosteroids. Methods Patients (n = 144) with class III or class IV lupus nephritis were randomized 1:1 to receive rituximab (1,000 mg) or placebo on days 1, 15, 168, and 182. The primary end point was renal response status at week 52. Results Rituximab depleted peripheral CD19+ B cells in 71 of 72 patients. The overall (complete and partial) renal response rates were 45.8% among the 72 patients receiving placebo and 56.9% among the 72 patients receiving rituximab (P = 0.18); partial responses accounted for most of the difference. The primary end point (superior response rate with rituximab) was not achieved. Eight placebo‐treated patients and no rituximab‐treated patients required cyclophosphamide rescue therapy through week 52. Statistically significant improvements in serum complement C3, C4, and anti–double‐stranded DNA (anti‐dsDNA) levels were observed among patients treated with rituximab. In both treatment groups, a reduction in anti‐dsDNA levels greater than the median reduction was associated with reduced proteinuria. The rates of serious adverse events, including infections, were similar in both groups. Neutropenia, leukopenia, and hypotension occurred more frequently in the rituximab group. Conclusion Although rituximab therapy led to more responders and greater reductions in anti‐dsDNA and C3/C4 levels, it did not improve clinical outcomes after 1 year of treatment. The combination of rituximab with MMF and corticosteroids did not result in any new or unexpected safety signals.Keywords
This publication has 47 references indexed in Scilit:
- In Situ B Cell-Mediated Immune Responses and Tubulointerstitial Inflammation in Human Lupus NephritisThe Journal of Immunology, 2011
- Updates on the Treatment of Lupus NephritisJournal of the American Society of Nephrology, 2010
- Rituximab versus Cyclophosphamide for ANCA-Associated VasculitisThe New England Journal of Medicine, 2010
- Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS studyRheumatology, 2009
- Oral Cyclophosphamide for Lupus GlomerulonephritisClinical Journal of the American Society of Nephrology, 2009
- Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus NephritisJournal of the American Society of Nephrology, 2009
- An update on the use of mycophenolate mofetil in lupus nephritis and other primary glomerular diseasesNature Reviews Nephrology, 2009
- B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of responseAnnals Of The Rheumatic Diseases, 2007
- B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose‐escalation trial of rituximabArthritis & Rheumatism, 2004
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992